Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients

References

• Su J, Li C-X, Liu H-Y, et al. The airway microbiota signatures of infection and rejection in lung transplant recipients. Microbiol Spectr. 2022;10(2):e0034421. doi:10.1128/spectrum.00344-21
   PubMed Web of Science ®Google Scholar
• Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1060–1072. doi:10.1016/j.healun.2021.07.021
   PubMedGoogle Scholar
• De Muynck B, Van Herck A, Sacreas A, et al. Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis. Eur Respir J. 2020;56(4). doi:10.1183/13993003.01720-2020
   PubMed Web of Science ®Google Scholar
• Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: multiorgan Transplantation. J Heart Lung Transplant. 2018;37(10):1169–1183. doi:10.1016/j.healun.2018.07.020
   PubMedGoogle Scholar
• Di Nardo M, Tikkanen J, Husain S, et al. Postoperative management of lung transplant recipients in the intensive care unit. Anesthesiology. 2022;136(3):482–499. doi:10.1097/aln.0000000000004054
   PubMed Web of Science ®Google Scholar
• Perch M, Hayes D, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease. J Heart Lung Transplant. 2022;41(10):1335–1347. doi:10.1016/j.healun.2022.08.007
   PubMed Web of Science ®Google Scholar
• Paglicci L, Borgo V, Lanzarone N, et al. Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients. Eur J Clin Microbiol Infect Dis. 2021;40(6):1271–1282. doi:10.1007/s10096-021-04153-1
   PubMed Web of Science ®Google Scholar
• Aguado JM, Silva JT, Fernández-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2018;32(1):36–57. doi:10.1016/j.trre.2017.07.001
   Web of Science ®Google Scholar
• Dettori M, Riccardi N, Canetti D, et al. Infections in lung transplanted patients: a review. Pulmonology. 2022. doi:10.1016/j.pulmoe.2022.04.010
   PubMedGoogle Scholar
• van Delden C, Stampf S, Hirsch HH, et al. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study. Clin Infect Dis. 2020;71(7):e159–e169. doi:10.1093/cid/ciz1113
   PubMed Web of Science ®Google Scholar
• Bodro M, Sabé N, Tubau F, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation. 2015;99(3):616–622. doi:10.1097/tp.0000000000000366
   PubMed Web of Science ®Google Scholar
• Camargo LF, Marra AR, Pignatari AC, et al. Nosocomial bloodstream infections in a nationwide study: comparison between solid organ transplant patients and the general population. Transpl Infect Dis. 2015;17(2):308–313. doi:10.1111/tid.12356
   PubMed Web of Science ®Google Scholar
• van den Bogaart L, Manuel O. Antibiotic therapy for difficult-to-treat infections in lung transplant recipients: a practical approach. Antibiotics. 2022;11(5). doi:10.3390/antibiotics11050612
   Google Scholar
• Liu T, Zhang Y, Wan Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infect Drug Resist. 2018;11:2345–2356. doi:10.2147/idr.S180283
   PubMed Web of Science ®Google Scholar
• Zhong ZQ, Luo AJ, Wan QQ, Ye QF. Pseudomonas aeruginosa infection among liver transplant recipients: a clinical analysis of 15 cases. Transplant Proc. 2016;48(6):2130–2134. doi:10.1016/j.transproceed.2016.03.052
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8(1):71–93. doi:10.1586/eri.09.108
   PubMed Web of Science ®Google Scholar
• Hu Y, Qing Y, Chen J, et al. Prevalence, risk factors, and molecular epidemiology of intestinal carbapenem-resistant Pseudomonas aeruginosa. Microbiol Spectr. 2021;9(3):e0134421. doi:10.1128/Spectrum.01344-21
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/s1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Das S, Li J, Riccobene T, et al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/aac.02187-18
   Web of Science ®Google Scholar
• Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10(4):1989–2034. doi:10.1007/s40121-021-00507-6
   PubMed Web of Science ®Google Scholar
• Chen J, Liang Q, Chen X, et al. Ceftazidime/Avibactam versus Polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection. Infect Drug Resist. 2022;15:655–667. doi:10.2147/idr.S350976
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis. 2019;6(12):ofz522. doi:10.1093/ofid/ofz522
   PubMed Web of Science ®Google Scholar
• Rodríguez-Núñez O, Ripa M, Morata L, et al. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136–139. doi:10.1016/j.jgar.2018.07.010
   PubMed Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics. 2020;9(2). doi:10.3390/antibiotics9020071
   Google Scholar
• Corbella L, Boán J, San-Juan R, et al. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents. 2022;59(2):106517. doi:10.1016/j.ijantimicag.2021.106517
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Husain S, Mooney ML, Danziger-Isakov L, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant. 2011;30(4):361–374. doi:10.1016/j.healun.2011.01.701
   PubMed Web of Science ®Google Scholar
• Gu J, Xu J, Zuo TT, Chen YB. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections. J Glob Antimicrob Resist. 2021;26:20–25. doi:10.1016/j.jgar.2021.04.022
   PubMed Web of Science ®Google Scholar
• Chen F, Zhong H, Yang T, et al. Ceftazidime-avibactam as salvage treatment for infections due to carbapenem-resistant Klebsiella pneumoniae in liver transplantation recipients. Infect Drug Resist. 2021;14:5603–5612. doi:10.2147/idr.S342163
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, M100. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• Stone GG, Newell P, Gasink LB, et al. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018;73(9):2519–2523. doi:10.1093/jac/dky204
   PubMed Web of Science ®Google Scholar
• Gill CM, Aktaþ E, Alfouzan W, et al. The ERACE-PA global surveillance program: ceftolozane/tazobactam and Ceftazidime/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021;40(12):2533–2541. doi:10.1007/s10096-021-04308-0
   PubMed Web of Science ®Google Scholar
• Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from Blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61(10). doi:10.1128/aac.00875-17
   PubMed Web of Science ®Google Scholar
• Møller DL, Sørensen SS, Perch M, et al. Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. Clin Microbiol Infect. 2022;28(3):391–397. doi:10.1016/j.cmi.2021.07.021
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhong J, Ding H, Liao G. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation. Infect Drug Resist. 2021;14:5165–5174. doi:10.2147/idr.S343505
   PubMed Web of Science ®Google Scholar
• Chen W, Sun L, Guo L, et al. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli. Ann Transl Med. 2020;8(3):39. doi:10.21037/atm.2019.10.40
   PubMed Web of Science ®Google Scholar